CG Results Healthcare has advised Orphan Reach on its acquisition by Emmes

CG Results Healthcare is delighted to have been the exclusive advisor to Orphan Reach, a Clinical Research Organisation (CRO) dedicated to rare diseases, on its acquisition by Emmes, a global, full-service CRO dedicated to supporting the advancement of public health and biopharmaceutical innovation.

Headquartered in the United Kingdom, Orphan Reach has built a reputation for outstanding clinical research addressing rare diseases. Created in 2002, the company has management teams in Europe, Asia and the U.S., and supports patients with rare diseases in more than 70 countries. The team’s goal is to accelerate access to new treatments in a wide range of orphan therapeutic areas.

This is Emmes’ second acquisition in the past four months, following the acquisition of Neoxs.r.o., an EU-based CRO, in December 2020. Neox and Orphan Reach expand Emmes’ global reach with their international footprints and add a larger and more diverse set of biopharmaceutical clients.

This transaction highlights CG Results Healthcare’s position as the leading advisor to fast-growth CRO businesses having recently advised SQN Clinical on its acquisition by Veristat, Charterhouse on its investment in Phastar and AdmeScope on its acquisition by MercachemSyncom.